Product Information
Registration Status: ActiveSIN15437P
ZYRTEC-R ORAL SOLUTION 1 MG/ML is approved to be sold in Singapore with effective from 2018-02-27. It is marketed by GLAXOSMITHKLINE PTE LTD, with the registration number of SIN15437P.
This product contains Cetirizine 5 MG/5 ML in the form of SOLUTION. It is approved for ORAL use.
This product is manufactured by AESICA PHARMACEUTICALS S.R.L in ITALY.
It is an Over-the-counter Medicine that can be freely obtained from any retailer
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects. [PubChem]
Indication
For the relief of symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis and the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria
Mechanism of Action
Cetirizine competes with histamine for binding at H1-receptor sites on the effector cell surface, resulting in suppression of histaminic edema, flare, and pruritus. The low incidence of sedation can be attributed to reduced penetration of cetirizine into the CNS as a result of the less lipophilic carboxyl group on the ethylamine side chain.
Pharmacokinetics
- Absorption
- mean peak plasma concentration (Cmax) of 114 ng/mL at a time (Tmax) of 2.2 hours postdose was observed for cetirizine
- Distribution
- Metabolism
- Elimination
Clearance
* 53 mL/min [healthy]
Toxicity
Somnolence (sleepiness or unusual drowsiness), restlessness, irritability
Active Ingredient/Synonyms
Cetirizin | Cetirizina | Cetirizinum | Cetirizine |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.